

+

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application No.	09/841,744
				Filing Date	April 24, 2001
				First Named Inventor	Jorge F. DiMartino
				Art Unit	1653
				Examiner Name	Chih-Min Kam
Sheet	1	Of	2	Attorney Docket No. 12636-891	
OTHER PRIOR ART - NON PATENT RELATED DOCUMENTS					
Examiner Initials*	Cite No.†	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published			T‡
CMK		BAYLIN, S.B., et al., "Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia," <i>Cancer Res.</i> , (1998) 72:141-196.			
		DASKALAKIS, M., et al., "Expression of a Hypermethylated and Silenced P15/INK4B Gene in a Subgroup of MDS Patients is Restored by Treatment With The Methylation Inhibitor 5-AZA-2'-Deoxycytidine," <i>Abstracts Leukemia Research</i> (2001) Suppl. No. 1, S16-S17.			
		ESTELLER, M., "A Gene Hypermethylation Profile of Human Cancer," <i>Cancer Research</i> (2001) 61:3225-3229.			
		ESTELLER, M., "CpG Island Hypermethylation and Tumor Suppressor Genes: a Booming Present, a Brighter Future," <i>Oncogene</i> (2002) 21:5427-5440.			
		ESTELLER, M., "Epigenetic Lesions Causing Genetic Lesions in Human Cancer: Promoter Hypermethylation of DNA Repair Genes," <i>European Journal of Cancer</i> (2000) 36:2294-2300.			
		GAGNON, J., et al., "Interaction of 5-aza-2'-deoxycytidine and Depsipeptide on Antineoplastic Activity and Activation of 14-3-3σ, E-Cadherin And Tissue Inhibitor of Metalloproteinase 3 Expression in Human Breast Carcinoma Cells," <i>Anti-Cancer Drugs</i> , (2003), 14(3):193-202.			
		JONES, P.A., "DNA Methylation And Cancer," <i>Oncogene</i> , (2002) 21:5358-5360.			
		JONES, P.A., et al., "The Fundamental Role of Epigenetic Events in Cancer," <i>Nature Reviews/Genetics</i> , (2002) 3:415-428.			
		JONES, P.A., et al., "The Role of DNA Methylation in Cancer," <i>Adv. Cancer Res.</i> , (1990) 54:1-23.			
		KARPF, A.R., et al., "Reactivating The Expression of Methylation Silenced Genes in Human Cancer," <i>Oncogene</i> , (2002) 21:5496-5503.			
		LA ROSEE, P., et al., "In Vitro Efficacy of Combined Treatment Depends on the Underlying Mechanism of Resistance in Imatinib-Resistant Bcr-Abl positive Cell Lines," <i>Blood First Edition Paper</i> , prepublished online (2003) DOI 10.1182/blood-2003-04-1074, pp. 1-39.			
		NEPHEW, K.P., et al., "Epigenetic Gene Silencing in Cancer Initiation And Progression," <i>Cancer Letters</i> 190, (2003) pp. 125-133.			
		PAZ, M.F., et al., "A Systematic Profile of DNA Methylation in Human Cancer Cell Lines," <i>Cancer Research</i> 63, (2003) 1114-1121.			
CMK		PRIMEAU, M., et al., "Synergistic Antineoplastic Action of DNA Methylation Inhibitor 5-AZA-2'-Deoxycytidine and Histone Deacetylase Inhibitor Depsipeptide on Human Breast Carcinoma Cells," <i>Int. J. Cancer</i> , (2003) 103:177-184.			
EXAMINER SIGNATURE		DATE CONSIDERED		5/9/04	

2408514.1.DOC

Attorney Docket No. 12636-891



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application No.	09/841,744		
		Filing Date	April 24, 2001		
		First Named Inventor	Jorge F. DiMartino		
		Art Unit	1653		
		Examiner Name	Chih-Min Kam		
Sheet	2	Of	2	Attorney Docket No.	12636-891
OTHER PRIOR ART - NON PATENT RELATED DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published			T ²
CMK		SANTINI, V., et al., "Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications," <i>Annals of Internal Medicine</i> (2001) 134:573-586.			
		SCHRUMP, D.S., et al., "Phase I Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients With Malignancies Involving Lungs or Pleura," <i>Clinical Lung Cancer</i> , (2002) 186-192.			
		SHAKER, S., et al., "Preclinical Evaluation of Antineoplastic Activity of Inhibitors of DNA Methylation (5-aza-2'-deoxycytidine) and Histone Deacetylation (Trichostatin A, Depsipeptide) in Combination Against Myeloid Leukemic Cells," <i>Leukemia Research</i> 27, (2003) 437-444.			
		SMIRAGLIA, D.J., et al., "The Study of Aberrant Methylation in Cancer via Restriction Landmark Genomic Scanning," <i>Oncogene</i> , (2002) 21:5414-5426.			
		WAJED, S.A., et al., "DNA Methylation: An Alternative Pathway to Cancer," <i>Annals of Surgery</i> (2001), 234(1):10-20.			
CMK		WEISER, T.S., "Sequential 5-Aza-2'-Deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells And Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1," <i>Journal of Immunotherapy</i> , (2001), 24(2):151-161.			
EXAMINER SIGNATURE	CHL / ~		DATE CONSIDERED	5/9/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.